 Shares of Xenetic Biosciences Inc. skyrocketed on massive volume toward a 17-month high in morning trading Wednesday, after the Massachusetts-based biopharmaceutical company said its partner PJSC Pharmsynthez provided positive data from a Phase 3 trial of its treatment for anemia patients with kidney disease. The stock blasted 349.4 higher on volume of 140.3 million shares, which was enough to make it the most actively traded on major U.S. exchanges, and compared with the full-day average of about 327,366 shares. 